Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety
Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta · 2026
Read Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety by Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13323781.txt.
Description
Federica Vinciguerra and co-authors tested tirzepatide for patients who regained weight after bariatric surgery or endoscopic bariatric therapy. Their 2026 observational cohort followed 34 patients, 32 after surgery and 2 after endoscopic therapy, measuring weight, body mass index categories, and side effects at starting and after 24 weeks of treatment. Regained weight after these procedures is a lasting clinical problem that can undo long-term success.
Total weight loss averaged 5.6%, waist circumference fell significantly, and most patients moved to a lower body mass index category, many reaching overweight or normal weight status. Side effects were confined to the gut, constipation, diarrhea, and nausea, and were generally mild, with none forcing a stop to treatment. The authors present tirzepatide as a promising nonsurgical option for this group, while noting that the evidence is preliminary and observational.
Catalog record
| CREATOR | Federica Vinciguerra, Carla Di Stefano, Fabio Guccione, Claudia Degano, Stefania Nigro, Roberto Baratta, Luigi Piazza, Giuseppe Navarra, Lucia Frittitta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |